Frontlight ResearchEarly access
Amyloidosis trials in United Kingdom
13 of 20 trials · From ClinicalTrials.gov, checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleTRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
- Where
- Bellshill, Birmingham, Cardiff, London, Manchester
- Age
- 18 years to 85 years
- People
- 2,250 worldwide
- Run by
- Alnylam Pharmaceuticals
See details and how to joinNCT07052903 · EU 2024-519917-72-00 - Phase 3Taking peopleMAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
- Where
- Birmingham, Cardiff, Glasgow, Hexham, Liverpool, London, Manchester
- Age
- 18 years to 90 years
- People
- 1,200 worldwide
- Run by
- Intellia Therapeutics
See details and how to joinNCT06128629 · EU 2023-507220-23-00 - Phase 1Taking peopleA Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
- Where
- London, Sutton
- Age
- 18 years and over
- People
- 180 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT05652335 · EU 2023-503679-12-00 - Phase 2Taking peopleA Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis
- Where
- Liverpool, London
- Age
- 18 years to 64 years
- People
- 60 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07224672 · EU 2025-522803-60-00 - Phase 3Enrolling by invitationA Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
- Where
- Bellshill, Birmingham, Cardiff, Hexham, London, Manchester
- Age
- 18 years and over
- People
- 700 worldwide
- Run by
- Alnylam Pharmaceuticals
See details and how to joinNCT06679946 - Phase 3Taking peopleCLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
- Where
- Bellshill, Birmingham, Cardiff, Liverpool, London, Manchester
- Age
- 18 years and over
- People
- 1,280 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT07207811 - Phase 3Taking peopleTRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
- Where
- London
- Age
- 18 years to 85 years
- People
- 125 worldwide
- Run by
- Alnylam Pharmaceuticals
See details and how to joinNCT07223203 · EU 2025-522544-40-00 - Phase 3Not yet taking people in United KingdomAn Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy
- Where
- Birmingham, Cardiff, Glasgow, London, Manchester
- People
- 1,180 worldwide
- Run by
- Alexion Pharmaceuticals, Inc.
See details and how to joinNCT07789483 · EU 2026-526755-57-00 - Phase 1/2Taking peopleA Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
- Where
- London, Manchester
- Age
- 18 years and over
- People
- 220 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT06292780 · EU 2023-507809-34-00 - Phase 3Taking peopleAcoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
- Where
- London
- Age
- 18 years to 75 years
- People
- 587 worldwide
- Run by
- Eidos Therapeutics, a BridgeBio company
See details and how to joinNCT06563895 · EU 2024-513547-82-00 - Phase 1/2WithdrawnA Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
- Where
- London
- Age
- 18 years and over
- People
- 91 worldwide
- Run by
- Alexion Pharmaceuticals, Inc.
See details and how to joinNCT07081646 - No phaseTaking peoplePATHWAY-RCT: Preventing Admission To Hospital With Attr cardiomyopathY
- Where
- London
- Age
- 18 years and over
- People
- 320
- Run by
- Richmond Research Institute
See details and how to joinNCT05098665 - Phase 3Enrolling by invitationAn Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
- Where
- Bellshill, Cardiff, Edgbaston, Hampstead, Liverpool, London, Manchester
- Age
- 18 years and over
- People
- 1,400 worldwide
- Run by
- Ionis Pharmaceuticals, Inc.
See details and how to joinNCT05667493